Abstract:10564 Background: Colorectal cancer (CRC) represents the 4th common cancer in China with more than 170,000 new cases annually. In Shanghai, CRC increased rapidly during the latest decade (second most common cancer), and its early detection remains a major public health challenge. Fecal occult blood testing and colonoscopy aim to identify CRC patients from symptomatic or asymptomatic people, but both require heavy logistics. A simpler blood-based test would represent an interesting alternative. DNA-microarrays and PAXgene are used to study the gene expression repertoire in peripheral blood samples, suitable for new biomarker discovery. Methods: 119 CRC patients without previous radiotherapy or chemotherapy and 101 colonoscopy-negative controls without polyps or CRC were enrolled in our study. RNA extracted from peripheral blood samples collected in PAXgene tubes, were analysed after NuGEN WT-Ovation RNA amplification, using Affymetrix GeneChip HG-U133 Plus 2.0 Array. Molecular signature analysis was performed based on 5-fold cross validation process. In each iteration, 95 CRC and 80 control samples were randomly assigned to training set for gene selection and classification model training. The retained 24 CRC and 21 control samples were used as test set to assess the classification model performance. The process was repeated for 1000 iterations. Eventually, accuracy, sensitivity and specificity were used to assess the overall performance. Results: One thousand of 100-gene based SVM classifiers were studied. The performance observed was overall accuracy 0.93 (95%CI: 0.928-0.932), sensitivity 0.93 (95%CI: 0.926-0.934) and specificity 0.92 (95%CI: 0.916-0.924). The majority of selected genes represent cell death, cell adhesion, immune system development and signal transduction information, indicating the molecular changes occurring during colorectal cancer progression. Conclusions: Our results demonstrate the feasibility of gene expression profiling in peripheral whole blood for biomarker discovery for early detection of colorectal cancer. Validation of these findings in larger independent series are ongoing, strongly motivated by the performance observed at this stage. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration bioMerieux

Use of Peripheral Blood Mrna Signatures to Distinguish Colorectal Cancer Patients from Colonoscopy-Negative Patients

Novel Blood-Based, Five-Gene Biomarker Set For The Detection Of Colorectal Cancer

Peripheral blood mRNA signature for colorectal cancer screening.

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

Data from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer

An 18-Gene Blood-Based Ivd Test for Colorectal Cancer Early Detection with High Sensitivity and Specificity

Using peripheral blood mRNA signature to distinguish between breast cancer and benign breast disease in non-conclusive mammography patients.

Use of Peripheral Blood Mrna Signature to Distinguish Patients with Breast Cancer from Benign Breast Disease and Nonconclusive Mammography.

P2.11-01 Blood Transcriptomics Enables Detection of Pre-Invasive and Minimally-Invasive Lung Adenocarcinoma

Decrease in natural killer cell associated gene expression as a major characteristic of the immune status in the bloodstream of colorectal cancer patients.

The synchronous upregulation of a specific protein cluster in the blood predicts both colorectal cancer risk and patient immune status

Sensitive detection of colorectal cancer in peripheral blood by a novel methylation assay

DNA methylation profiling from circulating tumor DNA for early-detection of colorectal cancer.

Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study

Discovery and Validation of Methylation Signatures in Circulating Cell-Free DNA for the Detection of Colorectal Cancer

B-382 Accurate and Early Detection of Colorectal Cancer Using a Multilocus DNA Methylation Markers-based Testing in Peripheral Blood Mononuclear Cells

Long non-coding RNAs LOC285194, RP11-462C24.1 and Nbla12061 in serum provide a new approach for distinguishing patients with colorectal cancer from healthy controls

Integration of multiomics features for blood-based early detection of colorectal cancer

Gene Expression Analysis of Peripheral Blood Cells Reveals Toll-like Receptor Pathway Deregulation in Colorectal Cancer.

Gene Expression Profiling-Derived Immunohistochemistry Signature with High Prognostic Value in Colorectal Carcinoma

Exploration and validation of a combined immune and metabolism gene signature for prognosis prediction of colorectal cancer